1. Introduction {#sec1-jcm-08-01961}
===============

Blood transfusion is an urgent intervention executed to restore lost components of blood on a short-term basis \[[@B1-jcm-08-01961]\]. Transfusion reactions are also called transfusion-associated adverse reactions (TAARs), which are defined as adverse events associated with blood transfusion with one of the components of blood \[[@B2-jcm-08-01961]\]. Acute transfusion reactions are distinguished from delayed transfusion reactions by occurring within 24 h after transfusion. The adverse reactions commonly occur in hospital, and the symptoms include fever, chills, rigors, dyspnea, hypotension, itching, and urticaria. They may range in severity from mild to life-threatening \[[@B2-jcm-08-01961],[@B3-jcm-08-01961]\].

The causes of TAARs were suggested according to individual reactions \[[@B4-jcm-08-01961]\]. Leukocytes and cytokines in blood units have been known to be involved in febrile non-hemolytic transfusion reaction (FNHTR) \[[@B5-jcm-08-01961]\]. Human leukocyte antigen (HLA) antibodies would be induced in recipients if the HLA of transfused products was different from those in recipients, and FNHTR would occur when the same HLA antigens are transfused next time \[[@B6-jcm-08-01961]\]. Therefore, these transfusion reactions commonly occurred in multiparous women \[[@B7-jcm-08-01961]\] and multiply transfused patients \[[@B8-jcm-08-01961]\].

Leukocyte-poor blood components were used to avoid alloimmunization to HLA antigens for recipients with a history of FNHTR and avoid being infected by cytomegalovirus (CMV) \[[@B9-jcm-08-01961]\]. Moreover, the development of FNHTR was gradually decreased by using pre-storage leukoreduced blood components, because of less accumulation of cytokines in the blood components \[[@B10-jcm-08-01961]\]. Van de Watering LM et al. proposed that leukocyte-depleted blood transfusion is beneficial for postoperative complications in patients undergoing cardiac surgery \[[@B11-jcm-08-01961]\]. K Rajesh et al. indicated that execution of pre-storage leukoreduction significantly decreased FNHTR occurrence \[[@B12-jcm-08-01961]\]. However, FNHTR still presents when transfusing pre-storage leukoreduced blood components. According to a previous study, FNHTR would occur when human platelet antigen (HPA) was unmatched between donor and recipient, and HPA-2 was related to FNHTR \[[@B13-jcm-08-01961]\].

Hematopoietic stem cells (HSCs) are precursors that have the ability to differentiate into all types of blood cells, including leukocytes, erythrocytes, and platelets, which are found in blood products \[[@B14-jcm-08-01961]\]. In 2009, Li XC et al. pointed out that costimulatory molecules play an important role in acute graft-versus-host disease (GVHD) \[[@B15-jcm-08-01961]\] and it was found that polymorphism of costimulatory molecules, including CTLA4 and ICOS, might be associated with GVHD in allogeneic hematopoietic stem cell transplantation (HSCT) \[[@B16-jcm-08-01961]\]. Moreover, both CTLA4 and ICOS gene polymorphisms in the donor and recipient might be of importance for the outcome of allogeneic HSCT \[[@B17-jcm-08-01961]\]. In addition, there were several studies on HSCT that showed that CTLA4 SNPs have been associated with differences in relapse free survival (RFS), overall survival (OS), and GVHD, but there were discordant results between these investigators \[[@B18-jcm-08-01961],[@B19-jcm-08-01961],[@B20-jcm-08-01961],[@B21-jcm-08-01961],[@B22-jcm-08-01961]\].

Blood transfusion is similar to transplantation in that it implants allogeneic cells or organs into a recipient. In addition, GVHD after transplantation results from the immune response, the same as TAARs after transfusion. Herein, we investigated the correlation of CTLA4 gene polymorphism and transfusion reactions, in order to uncover potential immune regulation affected by costimulatory molecules which could predict transfusion reaction occurrence and guide preventive actions.

2. Experimental Section {#sec2-jcm-08-01961}
=======================

2.1. Study Subjects {#sec2dot1-jcm-08-01961}
-------------------

This study was approved by the Institutional Review Board of Chang Gung Memorial Hospital (CGMH) with the approval ID of 1809100035. Nineteen patients with TAARs after leukoreduced blood products (leukocyte-poor RBC or leukocyte-poor platelet) transfusion at Linkou CGMH and 20 healthy subjects were included in the study. Investigation of TAARs was performed by clinical pathologists in Department of Laboratory Medicine at Linkou CGMH, and diagnostic criteria of TAARs were according to Hemovigilance Module Surveillance Protocol of National Healthcare Safety Network (NHSN) Biovigilance Component \[[@B23-jcm-08-01961]\].

2.2. DNA Extraction {#sec2dot2-jcm-08-01961}
-------------------

Peripheral blood samples were collected in EDTA-coated vacuum tubes, and genomic DNA was extracted by using QIAamp DNA Mini kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions. DNA concentration and purity were evaluated by measuring the optical density at 260 and 280 nm through a UV spectrometer.

2.3. PCR Amplification {#sec2dot3-jcm-08-01961}
----------------------

The PCR mixture contained 1 µL DNA, 10 µL Hotstar Taq DNA Polymerase (Qiagen GmbH, Hilden, Germany), 1 µL CTLA4 forward primer (10 Mµ), 1 µL CTLA4 reverse primer (10 Mµ), and 12 µL ddH2O. The CTLA4 primers were shown in [Table 1](#jcm-08-01961-t001){ref-type="table"}. The PCR program was 1 cycle of 95 ℃ for 10 min, 35 cycles of 94 ℃ for 30 secs, 65.5 ℃ for 30 secs, and 72 ℃ for 1 min. The final elongation step was 3 min at 72 ℃ and then soaking at 10 ℃. For gel electrophoresis visualization, 5 μL of the PCR products was pipetted onto a 1.5% agarose gel and run at 100 V for 20 min. The PCR products were visualized under UV illumination to ensure the correctness.

2.4. Purifying and SNPs Analysis {#sec2dot4-jcm-08-01961}
--------------------------------

The PCR products were purified by enzyme, containing 2.5 µL shrimp alkaline phosphatase and 0.05 µL exonuclease I (New England Biolabs, UK), and the purified PCR products were sequenced using ABI PRISM 3730 DNA analyzer (Applied Biosystems, Foster City, CA). The analysis of SNPs was performed on the promoter region of CTLA4, and rs11571315, rs733618, rs4553808, rs11571316, rs62182595, rs16840252, rs5742909, and rs231775 were selected for genotyping.

2.5. Statistical Analysis {#sec2dot5-jcm-08-01961}
-------------------------

Statistical analysis was performed through SPSS (SPSS Inc. Released 2008. SPSS Statistics for Windows, Version 17.0. Chicago, USA). The allele frequency of each SNP was analyzed through the exact test to determine whether the SNPs departed from Hardy--Weinberg equilibrium (HWE). The genotype and allele frequencies of the CTLA4 gene were compared between healthy controls and patients with TAARs using the chi-square test or Fisher's exact test to appraise the association between TAARs and CTLA4 SNPs.

3. Results {#sec3-jcm-08-01961}
==========

Nineteen patients and 20 healthy subjects were included. Among 19 patients, there were 4 males and 15 females with a median age of 51 years (range from 2 to 88 years old). The types of TAARs the patients suffered from were allergic reaction (4 cases, 21%) and febrile non-hemolytic transfusion reaction (FNHTR, 15 cases, 79%) ([Table 2](#jcm-08-01961-t002){ref-type="table"}).

Selected CTLA4 gene SNPs (rs11571315, rs733618, rs4553808, rs11571316, rs62182595, rs16840252, rs5742909, and rs231775) were genotyped in patients and healthy controls. All SNPs were in accordance with the HWE in the control group (*p* \> 0.05) ([Table 3](#jcm-08-01961-t003){ref-type="table"}). Furthermore, there were 4 SNPs (rs4553808, rs62182595, rs16840252, and rs5742909) showing differences in allele frequency between patients with transfusion reaction and healthy controls ([Table 3](#jcm-08-01961-t003){ref-type="table"}). Among these SNPs, the frequency of "A" allele of rs4553808, "G" allele of rs62182595, "G" allele of rs16840252, and "C" allele of rs5742909 were significantly higher in patients than in controls (0% versus 15%; 0% versus 15%; 0% versus 17.5%; 0% versus 15%, respectively).

Moreover, the "A" allele of rs4553808, the "G" allele of rs62182595, the "G" allele of rs16840252, and the "C" allele of rs5742909 showed significantly higher risk of TAARs (OR = 2.357, 95%CI: 1.584--3.508, *p* = 0.02; OR = 2.357, 95%CI: 1.584--3.508, *p* = 0.02; OR = 2.462, 95%CI: 1.619--3.742, *p* = 0.008; OR = 2.357, 95%CI: 1.584--3.508, *p* = 0.02; OR = 2.357, 95%CI: 1.584--3.508, *p* = 0.02, respectively) ([Table 4](#jcm-08-01961-t004){ref-type="table"}). The genotype frequency of "CT" genotype in rs11571315 significantly differed between patients with transfusion reaction and healthy controls ([Table 4](#jcm-08-01961-t004){ref-type="table"}).

4. Discussion {#sec4-jcm-08-01961}
=============

According to our results, we demonstrated that 5 SNPs of CTLA4 were correlated with transfusion reactions, and the "A" allele of rs4553808, the "G" allele of rs62182595, the "G" allele of rs16840252, and the "C" allele of rs5742909 showed an increased risk of TAARs. Because these SNPs are in the promoter region of CTLA4, SNP polymorphisms may cause different levels of mRNA transcription, protein translation, and affect T-cell homeostasis \[[@B24-jcm-08-01961],[@B25-jcm-08-01961]\]. Consequently, it suggested that the transcription level of CTLA4 may be related to transfusion reactions. Inhibition of CTLA4 in CD4+CD25+ regulatory T cells (Treg cells) led to impairment of the suppressive function of these cells \[[@B26-jcm-08-01961]\], so CTLA4 gene polymorphism would affect Treg cells and induce TAARs.

A previous study indicated that SNP rs4553808 of CTLA4 is associated with human myasthenia gravis by involvement in transcriptional binding activity for Nuclear Factor I and c/EBPbeta, and G allele of rs4553808 was less frequent in patients with myasthenia gravis than in healthy controls \[[@B27-jcm-08-01961]\]. The genotypes of rs4553808 were all AA and had no G allele in our patient group, so it could be surmised that rs4553808 may participate in the binding of certain transcription factors that cause an immune response to transfused blood components and result in adverse transfusion reactions. The "T" allele of rs5742909 was shown to increase CTLA4 expression and decrease the risk of multiple sclerosis \[[@B28-jcm-08-01961]\] However, the "C" allele of rs5742909 showed an increased risk of TAARs, and it indicated that CTLA4 expression would be altered and cause TAARs. Because rs16840252, rs5742909, and rs4553808 are in strong linkage disequilibrium (LD), the function of rs16840252 could be influenced by rs5742909 or rs4553808 \[[@B28-jcm-08-01961]\]. This might explain why rs16840252 had the greatest effect on the risk of TAARs.

In [Table 5](#jcm-08-01961-t005){ref-type="table"}, we summarized several studies for clinical conditions of significant CTLA4 SNPs in this study. These SNPs were associated with immune-related diseases or conditions, including Grave's disease \[[@B29-jcm-08-01961]\], organ or stem cell transplantation \[[@B30-jcm-08-01961],[@B31-jcm-08-01961]\], susceptibility of cancer \[[@B32-jcm-08-01961],[@B33-jcm-08-01961],[@B34-jcm-08-01961]\], and thrombocytopenia \[[@B35-jcm-08-01961]\]. CTLA4 participates in immune regulation and genetic variations in CTLA4 gene would influence immune response and then alter the risk of suffering from a disease \[[@B36-jcm-08-01961]\]. Although the characteristics of allogeneic HSCT and blood transfusion are the same in injecting allogeneic cells into donor, the TAAR-related SNPs which were located in the promoter region in our study were different to those in previous studies for HSCT-related SNPs (rs231775 and rs3087243) \[[@B21-jcm-08-01961],[@B37-jcm-08-01961]\]. rs231775 is a CTLA4 SNP in exon 1 which encodes a signal peptide, and rs231775 abolishes CTLA4 protein expression \[[@B37-jcm-08-01961]\]; rs3087243 is located in the 3′UTR region which regulates mRNA stability \[[@B38-jcm-08-01961]\]. Therefore, mechanisms of CTLA4 influencing HSCT or causing transfusion reactions are different.

The types of TAARs included in the present study were allergic reaction and FNHTR, so these significant CTLA4 SNPs would explain the situation that these adverse reactions occur even when transfusing leukoreduced blood components. Moreover, HPA mismatch between donor and recipient would be associated with FNHTR in patients transfused with leukocyte-poor RBC \[[@B13-jcm-08-01961]\]. Therefore, CTLA4 SNPs and HPA should be further investigated to clarify the mechanisms of FNHTR occurrence in recipients of leukoreduced blood components.

5. Conclusions {#sec5-jcm-08-01961}
==============

In conclusion, the present study demonstrated the correlation between CTLA4 gene polymorphism and transfusion reaction, and alleles of 4 CTLA4 SNP with an increased risk of TAARs were found. It is important to explore the potential immune regulatory mechanism affected by SNPs of costimulatory molecules, as this could predict disease occurrence and guide preventive actions.
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jcm-08-01961-t001_Table 1

###### 

CTLA4 primers for promotor and exon 1.

  Primers   Sequence
  --------- ---------------------------------
  pF        5′ GGCAACAGAGACCCCACCGTT 3′
  pR        5′ GAGGACCTTCCTTAAATCTGGAGAG 3′
  E1F       5′ CTCTCCAGATTTAAGGAAGGTCCTC 3′
  E1R       5′ GGAATACAGAGCCAGCCAAGCC 3′

p: promoter, F: forward primer; R: reverse primer; E1: exon1.

jcm-08-01961-t002_Table 2

###### 

Characteristics of patients (*n* = 19) and healthy control (*n* = 20).

                                                         Patients, No. (%)             Controls, No. (%)
  ------------------------------------------------------ ----------------------------- --------------------------------
  **Median age of patients**                             51 (range, 2--88 years old)   22.8 (range, 22--24 years old)
  **Gender**                                                                           
  Male                                                   4 (21)                        5 (20)
  Female                                                 15 (79)                       15 (80)
  **Type of blood transfusion**                                                        
  Leukocyte-poor platelet                                10 (53)                       
  Leukocyte-poor RBC                                     9 (47)                        
  **Type of transfusion-associated adverse reactions**                                 
  Allergic reaction                                      4 (21)                        
  Febrile non-hemolytic transfusion reaction             15 (79)                       

jcm-08-01961-t003_Table 3

###### 

Allele frequencies in patients and controls and odds ratio for transfusion reaction.

  SNP          Position    Allele   Minor Allele Frequency   HWE *p* Value   Odds Ratio   *p* Value              
  ------------ ----------- -------- ------------------------ --------------- ------------ ---------------------- ----------
  rs11571315   203866178   C/T      0.211                    0.300           0.696        1.607 (0.572--4.512)   0.366
  rs733618     203866221   T/C      0.474                    0.475           0.900        1.228 (0.505--2.988)   0.651
  rs4553808    203866282   A/G      0                        0.150           0.732        2.118 (1.659--2.703)   0.026 \*
  rs11571316   203866366   A/G      0.211                    0.150           0.628        1.511 (0.470--4.853)   0.486
  rs62182595   203866465   A/G      0                        0.150           0.732        2.118 (1.659--2.703)   0.026 \*
  rs16840252   203866796   C/T      0                        0.175           0.638        2.152 (1.676--2.762)   0.012 \*
  rs5742909    203867624   C/T      0                        0.150           0.732        2.118 (1.659--2.703)   0.026 \*
  rs231775     203867991   A/G      0.263                    0.300           0.696        1.200 (0.446--3.227)   0.718

HWE: Hardy--Weinberg equilibrium; 95%CI: 95% confidence interval; \* *p* \< 0.05.

jcm-08-01961-t004_Table 4

###### 

Genotypes of *CTLA*4 SNPs and their correlations with risk of transfusion reaction.

  SNP          Genotype   Genotype Frequency   Odds Ratio              *p* Value               
  ------------ ---------- -------------------- ----------------------- ----------------------- ----------
  rs11571315   CC         3                    1                       3.563 (0.337--37.687)   0.342
  CT           2          10                   0.118 (0.021--0.649)    0.008 \*                
  TT           14         9                    3.422 (0.888--13.183)   0.069                   
  rs733618     CC         6                    4                       1.846 (0.428--7.962)    0.480
               CT         8                    11                      0.595 (0.168--2.113)    0.421
  TT           5          5                    1.071 (0.254--4.512)    1                       
  rs4553808    AA         19                   14                      2.357(1.584--3.508)     0.020 \*
               AG         0                    6                       0.424(0.285--0.631)     0.020 \*
  GG           0          0                    NA                      NA                      
  rs11571316   GG         14                   15                      0.933 (0.222--3.930)    0.342
               AG         2                    4                       0.471 (0.086--2.932)    1
  AA           3          1                    3.563 (0.337--37.687)   0.648                   
  rs62182595   GG         19                   14                      2.357 (1.584--3.508)    0.020 \*
               AG         0                    6                       0.424 (0.285--0.631)    0.020 \*
  AA           0          0                    NA                      NA                      
  rs16840252   CC         19                   13                      2.462 (1.619--3.742)    0.008 \*
               CT         0                    7                       0.406 (0.267--0.618)    0.008 \*
  TT           0          0                    NA                      NA                      
  rs5742909    CC         19                   14                      2.357 (1.584--3.508)    0.020 \*
               CT         0                    6                       0.424 (0.25--0.631)     0.020 \*
               TT         0                    0                       NA                      NA
  rs231775     GG         12                   9                       2.095 (0.581--7.555)    0.256
               AG         4                    10                      0.267 (0.065--1.091)    0.062
               AA         3                    1                       3.563 (0.337--37.687)   0.342

95%CI: 95% confidence interval; \*: *p* \< 0.05; NA: not applicable.

jcm-08-01961-t005_Table 5

###### 

Summary of *CTLA*4 SNPs included and significant in present study and related clinical conditions.

  SNP          Clinical Condition                          Reference
  ------------ ------------------------------------------- -------------------------
  rs5742909    Grave's disease                             \[[@B29-jcm-08-01961]\]
               long-term kidney allograft function         \[[@B30-jcm-08-01961]\]
               cancer predisposition                       \[[@B32-jcm-08-01961]\]
  rs4553808    viral infection in kidney transplantation   \[[@B31-jcm-08-01961]\]
               long-term kidney allograft function         \[[@B30-jcm-08-01961]\]
               cancer predisposition                       \[[@B32-jcm-08-01961]\]
  rs16840252   colorectal cancer                           \[[@B33-jcm-08-01961]\]
               gastric adenocarcinoma                      \[[@B34-jcm-08-01961]\]
  rs11571315   immune thrombocytopenia                     \[[@B35-jcm-08-01961]\]
